DRUG-INDUCED ACUTE RENAL FAILURE USING THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE
Author(s)
Alhammad AM, Al Hawaj MA, Alsalman AJ, Alhashem YN, Harpe SE, Smith WR, Brophy DFVirginia Commonwealth University, Richmond, VA, USA
Presentation Documents
OBJECTIVES: The incidence of acute renal failure (ARF) is increasing. A substantial proportion of these cases are due to drug-induced nephrotoxicity. Data from post-marketing surveillance programs, like the FDA Adverse Event Reporting System (AERS), can be useful in assessing the risk of adverse drug events. Our objective is to describe reports with ARF (cases) and reports without ARF (non-cases) and outcomes resulting from ARF using the AERS database. METHODS: Data were extracted from the AERS database from 2004–2009. All reports of cases and non-cases were described and analyzed in term of suspected drugs, health outcomes, and other characteristics. Descriptive statistics (frequencies and proportions) and Chi-square tests were used. RESULTS: The AERS data used in this study represents 2,231,689 reports from 184 countries with 27,190 involving reports of ARF (cases). There was approximately a two-fold increase in the percentage of reports of ARF from 2004 to 2009 (n = 3,594; 13% to n = 6,104; 22%, respectively). Most reports were submitted by manufacturers (cases = 89%, non-cases= 93%). The majority of reports were for infants (cases = 75%, non-cases = 57%). In cases, drugs were the primary suspect, the secondary suspect and concomitant in 18%, 14% and 66% of reports, respectively. The five drugs with the highest reported frequencies of ARF were rofecoxib, valacyclovir, metformin, simvastatin, and digoxin. Unfavorable outcomes were more likely to occur in cases than non-cases (death 24% vs. 12%, life threatening condition 21% vs. 5%, initial/prolonged hospitalization 76% vs. 33%, disability 6% vs. 4% and required intervention 4% vs. 2%; p-value <0.001, for all comparisons). CONCLUSIONS: These preliminary findings present an overall picture of reports with ARF. These findings can be informative for regulatory authorities and healthcare professionals. Additional analyses with reporting odd ratios (ROR) are needed to support these initial findings.
Conference/Value in Health Info
2011-05, ISPOR 2011, Baltimore, MD, USA
Value in Health, Vol. 14, No. 3 (May 2011)
Code
PUK3
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Urinary/Kidney Disorders